nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2025-12-1-77-88nodgo-1133Research ArticleПРАКТИЧЕСКИЕ ВОПРОСЫ ДЕТСКОЙ ОНКОЛОГИИ-ГЕМАТОЛОГИИPRACTICAL QUESTIONS OF PEDIATRIC ONCOLOGY-HEMATOLOGYРуководство по профилактике и коррекции нежелательных явлений у пациентов, получающих терапию препаратом динутуксимаб бетаGuidance for the prevention and management of adverse events in patients receiving dinutuximab beta therapyhttps://orcid.org/0000-0002-7846-3473СагоянГ. Б.SagoyanG. B.

Гарик Барисович Сагоян - старший научный сотрудник, врач-детский онколог детского онкологического отделения № 1 (химиотерапии опухолей торакоабдоминальной локализации) НИИ детской онкологии и гематологии им. акад. РАМН Л.А. Дурнова 

115522, Москва, Каширское шоссе, 23

Senior Researcher, Pediatric Oncologist Pediatric Oncology Department № 1 (Chemotherapy of Tumors of Thoracoabdominal Localization) of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov

23 Kashirskoe Shosse, Moscow, 115522

sagoyan-garik@mail.ruhttps://orcid.org/0000-0002-5489-1879СулеймановаА. М.SuleymanovaA. M.

старший научный сотрудник, врач-детский онколог детского онкологического отделения № 1 (химиотерапии опухолей торакоабдоминальной локализации) НИИ детской онкологии и гематологии им. акад. РАМН Л.А. Дурнова 

115522, Москва, Каширское шоссе, 23

Senior Researcher, Pediatric Oncologist Pediatric Oncology Department № 1 (Chemotherapy of Tumors of Thoracoabdominal Localization) of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov

23 Kashirskoe Shosse, Moscow, 115522

aminasuleymanova313@gmail.comhttps://orcid.org/0000-0003-1949-6280ПапянР. Х.PapyanR. Kh.

руководитель мультидисциплинарной группы по заболеваниям опорно-двигательной системы, педиатрический руководитель, старший научный сотрудник Научно-исследовательского института иммуноонкологии, заведующая отделением детской онкологии Гематологического центра им. проф. Р.О. Еоляна, преподаватель кафедры детской онкологии и гематологии Ереванского государственного медицинского университета, сопредседатель Рабочей группы по вопросам подростков и молодых людей Международного общества детской онкологии (SIOP)

0014, Ереван, ул. Нерсисян, 7

0014, Ереван, ул. Нерсисян, 7

Ереван, 0025, ул. Корюн, 2

Head of the Multidisciplinary Group on Diseases of the Musculoskeletal System, Pediatric Director, Senior Researcher; Head; Lecturer at the Department of Pediatric Oncology and Hematology

7 Nersisyan St., Yerevan, 0014

7 Nersisyan St., Yerevan, 0014

2 Koryun St., Yerevan, 0025

ruzannapapyan92@gmail.comhttps://orcid.org/0000-0002-1016-539XРубанскаяМ. В.RubanskayaM. V.

к.м.н., заведующая детским онкологическим отделением № 1 (химиотерапии опухолей торакоабдоминальной локализации) НИИ детской онкологии и гематологии им. акад. РАМН Л.А. Дурнова

115522, Москва, Каширское шоссе, 23

Cand. of Sci. (Med.), Head of the Pediatric Oncology Department № 1 (Chemotherapy of Tumors of Thoracoabdominal Localization) of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov

23 Kashirskoe Shosse, Moscow, 115522

marishvecova@mail.ruhttps://orcid.org/0000-0003-0390-8498КулеваС. А.KulyovaS. A.

д.м.н., профессор, заведующая детским онкологическим отделением, ведущий научный сотрудник научного отдела инновационных методов терапевтической онкологии и реабилитации, профессор учебно-методического отдела 

197758, Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

Dr. of Sci. (Med.), Professor, Head of Pediatric Oncology Department, Leading Researcher of the Research Department of Innovative Therapeutic Oncology and Rehabilitation Methods, Professor of the Training and Methodology Department 

68 Leningradskaya St., Pesochny, Saint Petersburg, 197758

kulevadoc@yandex.ruhttps://orcid.org/0000-0001-7805-5616МатинянН. В.MatinyaN. V.

д.м.н., заведующая отделом анестезиологии-реанимации НИИ детской онкологии и гематологии им. акад. РАМН Л.А. Дурнова; профессор кафедры детской анестезиологии и интенсивной терапии 

AuthorID: 884136

115522, Москва, Каширское шоссе, 23

117997, Москва, ул. Островитянова, 1

Dr. of Sci. (Med.), Head of the Department of Anesthesiology and Resuscitation of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov; Professor Department of Pediatric Anesthesiology and Intensive Care 

23 Kashirskoe Shosse, Moscow, 115522

1 Ostrovityanova St., Moscow, 117997

n9031990633@yandex.ruhttps://orcid.org/0009-0008-8044-570XГалансковаА. Г.GalanskovaA. G.

врач-детский онколог детского онкологического отделения № 1 (химиотерапии опухолей торакоабдоминальной локализации) НИИ детской онкологии и гематологии им. акад. РАМН Л.А. Дурнова

115522, Москва, Каширское шоссе, 23

Pediatric Oncologist Pediatric Oncology Department № 1 (Chemotherapy of Tumors of Thoracoabdominal Localization) of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov

23 Kashirskoe Shosse, Moscow, 115522

ag@galanskova.ruhttps://orcid.org/0009-0003-6559-5359СидороваД. Д.SidorovaD. D.

врач-детский онколог детского онкологического отделения № 1 (химиотерапии опухолей торакоабдоминальной локализации) НИИ детской онкологии и гематологии им. акад. РАМН Л.А. Дурнова 

115522, Москва, Каширское шоссе, 23

Pediatric Oncologist Pediatric Oncology Department № 1 (Chemotherapy of Tumors of Thoracoabdominal Localization) of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov

23 Kashirskoe Shosse, Moscow, 115522

darya.kochetova.1993@mail.ruhttps://orcid.org/0009-0009-5989-3521ТерехинаД. А.TerekhinaD. А.

врач-детский онколог детского онкологического отделения № 1 (химиотерапии опухолей торакоабдоминальной локализации) НИИ детской онкологии и гематологии им. акад. РАМН Л.А. Дурнова 

115522, Москва, Каширское шоссе, 23

Pediatric Oncologist Pediatric Oncology Department № 1 (Chemotherapy of Tumors of Thoracoabdominal Localization) of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov

23 Kashirskoe Shosse, Moscow, 115522

daria.terekhina1@yandex.ruhttps://orcid.org/0000-0001-5911-553XБелышеваТ. С.BelyshevaT. S.

д.м.н., профессор, ведущий научный сотрудник поликлинического отделения НИИ детской онкологии и гематологии им. акад. РАМН Л.А. Дурнова 

115522, Москва, Каширское шоссе, 23

Dr. of Sci. (Med.), Professor, Leading Researcher Polyclinic Department of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov

23 Kashirskoe Shosse, Moscow, 115522

klinderma@bk.ruhttps://orcid.org/0000-0002-2945-284XКиргизовК. И.KirgizovK. I.

к.м.н., заместитель директора по научной работе НИИ детской онкологии и гематологии им. акад. РАМН Л.А. Дурнова 

115522, Москва, Каширское шоссе, 23

Cand. of Sci. (Med.), Deputy Director for Scientific Work of Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov

23 Kashirskoe Shosse, Moscow, 115522

k.kirgizov@ronc.ruhttps://orcid.org/0000-0001-6131-1783ВарфоломееваС. Р.VarfolomeevaS. R.

д.м.н., профессор, директор НИИ детской онкологии и гематологии им. акад. РАМН Л.А. Дурнова 

115522, Москва, Каширское шоссе, 23

Dr. of Sci. (Med.), Professor, Director of the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov

23 Kashirskoe Shosse, Moscow, 115522

s.varfolomeeva@ronc.ruФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of RussiaRussian FederationНаучно-исследовательский институт иммуноонкологии; АОЗТ «Гематологический центр имени профессора Р.О. Еоляна» Mинздрава Республики Армения; Ереванский государственный медицинский университетАрменияImmune Oncology Research Institute; Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center named after Professor R.O. Yeolyan; Yerevan State Medical UniversityArmeniaФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова» Минздрава РоссииРоссияN.N. Petrov National Medical Research Center of Oncology, Ministry of Health of RussiaRussian FederationФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России; ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава РоссииРоссияN.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaRussian Federation2025230420251217788Copyright © Сагоян Г.Б., Сулейманова А.М., Папян Р.Х., Рубанская М.В., Кулева С.А., Матинян Н.В., Галанскова А.Г., Сидорова Д.Д., Терехина Д.А., Белышева Т.С., Киргизов К.И., Варфоломеева С.Р., 20252025Сагоян Г.Б., Сулейманова А.М., Папян Р.Х., Рубанская М.В., Кулева С.А., Матинян Н.В., Галанскова А.Г., Сидорова Д.Д., Терехина Д.А., Белышева Т.С., Киргизов К.И., Варфоломеева С.Р.Sagoyan G.B., Suleymanova A.M., Papyan R.K., Rubanskaya M.V., Kulyova S.A., Matinya N.V., Galanskova A.G., Sidorova D.D., Terekhina D.А., Belysheva T.S., Kirgizov K.I., Varfolomeeva S.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/1133

Руководство по профилактике и коррекции нежелательных явлений (НЯ) у пациентов, получающих терапию препаратом динутуксимаб бета, представляет собой рекомендации по оценке риска развития, профилактике и коррекции НЯ.

The guidelines for the prevention and management of adverse events in patients receiving dinutuximab beta therapy provide recommendations for assessing the risk of development, prevention and management of adverse events.

руководствонейробластомаиммунотерапиядинутуксимаб бетанежелательные явленияguidelinesneuroblastomaimmunotherapydinutuximab betaadverse eventsReferencesVoeller J., Sondel P.M. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma. J Pediatr Hematol Oncol. 2019;41(3):163–9. doi: 10.1097/MPH.0000000000001369.Voeller J., Sondel P.M. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma. J Pediatr Hematol Oncol. 2019;41(3):163–9. doi: 10.1097/MPH.0000000000001369.Нейробластома. Клинические рекомендации. ID: 78_2. [Электронный ресурс]: URL: https://cr.minzdrav.gov.ru/preview-cr/78_2 (дата обращения 20.03.2025).Neuroblastoma. Clinical guidelines. ID: 78_2. [Electronic resource]: URL: https://cr.minzdrav.gov.ru/preview-cr/78_2 (appeal date 20.03.2025). (In Russ.)].Qarziba (dinutuximab beta) Summary of Product Characteristics (28/01/2020). [Electronic resource]: URL: https://www.ema.europa.eu/en/documents/product-information/qarziba-epar-product-information_en.pdf. Accessed Dec 2020.Qarziba (dinutuximab beta) Summary of Product Characteristics (28/01/2020). [Electronic resource]: URL: https://www.ema.europa.eu/en/documents/product-information/qarziba-epar-product-information_en.pdf. Accessed Dec 2020.Hoy S.M. Dinutuximab: A Review in High-Risk Neuroblastoma. Target Oncol. 2016;11(2):247–53. doi: 10.1007/s11523-016-0420-2.Hoy S.M. Dinutuximab: A Review in High-Risk Neuroblastoma. Target Oncol. 2016;11(2):247–53. doi: 10.1007/s11523-016-0420-2.Mastrangelo S., Rivetti S., Triarico S., Romano A., Attinà G., Maurizi P., Ruggiero A. Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients. Int J Mol Sci. 2021;22(23):12648. doi: 10.3390/ijms222312648.Mastrangelo S., Rivetti S., Triarico S., Romano A., Attinà G., Maurizi P., Ruggiero A. Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients. Int J Mol Sci. 2021;22(23):12648. doi: 10.3390/ijms222312648.Nazha B., Inal C., Owonikoko T.K. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Front Oncol. 2020;10:1000. doi: 10.3389/fonc.2020.01000.Nazha B., Inal C., Owonikoko T.K. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Front Oncol. 2020;10:1000. doi: 10.3389/fonc.2020.01000.Parsons K., Bernhardt B., Strickland B. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies. Ann Pharmacother. 2013;47(2):210–8. doi: 10.1345/aph.1R353.Parsons K., Bernhardt B., Strickland B. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies. Ann Pharmacother. 2013;47(2):210–8. doi: 10.1345/aph.1R353.Шаманская Т.В., Качанов Д.Ю., Иванов Н.С., Рабаева Л.Л., Ядгаров М.Я., Зацаринная О.С., Уталиева Д.Т., Литвинов Д.В., Румянцев А.Г., Новичкова Г.А. Переносимость и токсичность индукционной химиоиммунотерапии с динутуксимабом бета у первичных пациентов с нейробластомой группы высокого риска. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2024;23(1):108–18. doi: 10.24287/1726-1708-2024-23-1-108-118.Shamanskaya T.V., Kachanov D.Yu., Ivanov N.S., Rabaeva L.L., Yadgarov M.Ya., Zatsarinnaya O.S., Utalieva D.T., Litvinov D.V., Rumyantsev A.G., Novichkova G.A. Tolerability and toxicity of induction chemoimmunotherapy with dinutuximab beta in newly diagnosed patients with high-risk neuroblastoma. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology. 2024;23(1):108–18. (In Russ.)].Кулева С.А., Варфоломеева С.Р., Киргизов К.И., Просекина Е.А., Романцова О.М., Горбунова Т.В. Многоцентровое открытое исследование III фазы по использованию динутуксимаба бета без/с химиотерапией по выбору исследователя у пациентов до 18 лет с костными и мягкотканными саркомами с положительным уровнем экспрессии GD2 и прогрессированием заболевания на фоне 1-й линии полихимиотерапии. Российский журнал детской гематологии и онкологии. 2024;11(2):12–20. doi: 10.21682/2311-1267-2024-11-2-12-20.Kulyova S.A., Varfolomeeva S.R., Kirgizov K.I., Prosekina E.A., Romantsova O.M., Gorbunova T.V. A phase III, multicenter, open-label study of dinutuximab beta without/with chemotherapy at the investigator’s choice in patients under 18 years old with bone and soft tissue sarcomas with positive expression GD2 and disease progression during the fi rst-line chemotherapy. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology. 2024;11(2):12–20. (In Russ.)].Государственный реестр лекарственных средств Министерства здравоохранения Российской Федерации, 2022. [Электронный ресурс]: URL: https://web.archive.org/web/20221227085254/https://grls.rosminzdrav.ru/Default.aspx. (дата обращения 27.02.2025).State Register of Medicines of the Ministry of Health of the Russian Federation, 2022. [Electronic resource]: URL: https://web.archive.org/web/20221227085254/https://grls.rosminzdrav.ru/Default.aspx. (appeal date 27.02.2025). (In Russ.)].Фасеева Н.Д., Кулева С.А., Иванова С.В., Гумбатова Э.Д., Сенчуров Е.М., Субора А.Ю., Михайлова Е.А., Гогун А.А., Изможерова Р.И., Борокшинова К.М. Опыт применения пассивной иммунотерапии у пациентов с нейробластомой группы высокого риска. Российский журнал детской гематологии и онкологии. 2019;6(4):33–9. doi: 10.21682/2311-1267-2019-6-4-33-39.Faseeva N.D., Kuleva S.A., Ivanova S.V., Gumbatova E.D., Senchurov E.M., Subora А.Yu., Mikhailova E.M., Gogun A.A., Izmozherova R.I., Borokshinova K.M. Passive immunotherapy experience in patients with high-risk neuroblastoma. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology. 2019;6(4):33–9. (In Russ.)].Ladenstein R., Pötschger U., Valteau-Couanet D., Luksch R., Castel V., Yaniv I., Laureys G., Brock P., Michon J.M., Owens C., Trahair T., Chan G.C.F., Ruud E., Schroeder H., Beck Popovic M., Schreier G., Loibner H., Ambros P., Holmes K., Castellani M.R., Gaze M.N., Garaventa A., Pearson A.D.J., Lode H.N. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1617–29. doi: 10.1016/S1470-2045(18)30578-3.Ladenstein R., Pötschger U., Valteau-Couanet D., Luksch R., Castel V., Yaniv I., Laureys G., Brock P., Michon J.M., Owens C., Trahair T., Chan G.C.F., Ruud E., Schroeder H., Beck Popovic M., Schreier G., Loibner H., Ambros P., Holmes K., Castellani M.R., Gaze M.N., Garaventa A., Pearson A.D.J., Lode H.N. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1617–29. doi: 10.1016/S1470-2045(18)30578-3.Ladenstein R., Pötschger U., Valteau-Couanet D., Gray J., Luksch R., Balwierz W., Castel V., Ash S., Beck-Popovic M., Laureys G., Chi Fung Chan G., Ruud E., Vettenranta K., Owens C., Schroeder H., Loibner H., Ambros P.F., Sarnacki S., Boterberg T., Lode H.N. Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front-line highrisk neuroblastoma patients: early results from the HR-NBL1/SIOPEN trial. J Clin Oncol. 2019;37:10013.Ladenstein R., Pötschger U., Valteau-Couanet D., Gray J., Luksch R., Balwierz W., Castel V., Ash S., Beck-Popovic M., Laureys G., Chi Fung Chan G., Ruud E., Vettenranta K., Owens C., Schroeder H., Loibner H., Ambros P.F., Sarnacki S., Boterberg T., Lode H.N. Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front-line highrisk neuroblastoma patients: early results from the HR-NBL1/SIOPEN trial. J Clin Oncol. 2019;37:10013.Ladenstein R., Pötschger U., Valteau-Couanet D., Luksch R., Castel V., Ash S., Laureys G., Brock P., Michon J.M., Owens C., Trahair T., Chi Fung Chan G., Ruud E., Schroeder H., Beck-Popovic M., Schreier G., Loibner H., Ambros P., Holmes K., Castellani M.R., Gaze M.N., Garaventa A., Pearson A.D.J., Lode H.N. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers (Basel). 2020;12(2):309. doi: 10.3390/cancers12020309.Ladenstein R., Pötschger U., Valteau-Couanet D., Luksch R., Castel V., Ash S., Laureys G., Brock P., Michon J.M., Owens C., Trahair T., Chi Fung Chan G., Ruud E., Schroeder H., Beck-Popovic M., Schreier G., Loibner H., Ambros P., Holmes K., Castellani M.R., Gaze M.N., Garaventa A., Pearson A.D.J., Lode H.N. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers (Basel). 2020;12(2):309. doi: 10.3390/cancers12020309.Balaguer J., García Hidalgo L., Hladun R., Márquez Vega C., Pérez Alonso V. Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma. Target Oncol. 2023;18(1):77–93. doi: 10.1007/s11523-022-00930-w.Balaguer J., García Hidalgo L., Hladun R., Márquez Vega C., Pérez Alonso V. Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma. Target Oncol. 2023;18(1):77–93. doi: 10.1007/s11523-022-00930-w.Barone G., Barry A., Bautista F., Brichard B., Defachelles A.S., Herd F., Manzitti C., Reinhardt D., Rubio P.M., Wieczorek A., van Noesel M.M. Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance. Paediatr Drugs. 2021;23(6):537–48. doi: 10.1007/s40272-021-00469-9.Barone G., Barry A., Bautista F., Brichard B., Defachelles A.S., Herd F., Manzitti C., Reinhardt D., Rubio P.M., Wieczorek A., van Noesel M.M. Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance. Paediatr Drugs. 2021;23(6):537–48. doi: 10.1007/s40272-021-00469-9.Wieczorek A., Manzitti C., Garaventa A., Gray J., Papadakis V., Valteau-Couanet D., Zachwieja K., Poetschger U., Pribill I., Fiedler S., Ladenstein R., Lode H.N. Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials. Cancers (Basel). 2022;14(8):1919. doi: 10.3390/cancers14081919.Wieczorek A., Manzitti C., Garaventa A., Gray J., Papadakis V., Valteau-Couanet D., Zachwieja K., Poetschger U., Pribill I., Fiedler S., Ladenstein R., Lode H.N. Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials. Cancers (Basel). 2022;14(8):1919. doi: 10.3390/cancers14081919.Olgun N., Cecen E., Ince D., Kizmazoglu D., Baysal B., Onal A., Ozdogan O., Guleryuz H., Cetingoz R., Demiral A., Olguner M., Celik A., Kamer S., Ozer E., Altun Z., Aktas S. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience. Front Oncol. 2022;12:1041443. doi: 10.3389/fonc.2022.1041443.Olgun N., Cecen E., Ince D., Kizmazoglu D., Baysal B., Onal A., Ozdogan O., Guleryuz H., Cetingoz R., Demiral A., Olguner M., Celik A., Kamer S., Ozer E., Altun Z., Aktas S. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience. Front Oncol. 2022;12:1041443. doi: 10.3389/fonc.2022.1041443.Wieczorek A., Zaniewska-Tekieli A., Ehlert K., Pawinska-Wasikowska K., Balwierz W., Lode H. Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma. Front Oncol. 2023;13:1082771. doi: 10.3389/fonc.2023.1082771.Wieczorek A., Zaniewska-Tekieli A., Ehlert K., Pawinska-Wasikowska K., Balwierz W., Lode H. Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma. Front Oncol. 2023;13:1082771. doi: 10.3389/fonc.2023.1082771.Lang P., Flaadt T., Ebinger M., Schlegel P., Lode H., Ladenstein R., Lang A.M., Ambross P., Schaefer J., Fuchs J., Loibner H., Schwinger W., Handgretinger R. Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR. Cancer Immunol Res. 2019;7(2 Suppl):Abstract nr A013.Lang P., Flaadt T., Ebinger M., Schlegel P., Lode H., Ladenstein R., Lang A.M., Ambross P., Schaefer J., Fuchs J., Loibner H., Schwinger W., Handgretinger R. Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR. Cancer Immunol Res. 2019;7(2 Suppl):Abstract nr A013.Siebert N., Eger C., Seidel D., Jüttner M., Zumpe M., Wegner D., Kietz S., Ehlert K., Veal G.J., Siegmund W., Weiss M., Loibner H., Ladenstein R., Lode H.N. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MAbs. 2016;8(3):604–16. doi: 10.1080/19420862.2015.1130196.Siebert N., Eger C., Seidel D., Jüttner M., Zumpe M., Wegner D., Kietz S., Ehlert K., Veal G.J., Siegmund W., Weiss M., Loibner H., Ladenstein R., Lode H.N. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MAbs. 2016;8(3):604–16. doi: 10.1080/19420862.2015.1130196.Siebert N., Troschke-Meurer S., Marx M., Zumpe M., Ehlert K., Gray J., Garaventa A., Manzitti C., Ash S., Klingebiel T., Beck J., Castel V., Valteau-Couanet D., Loibner H., Ladenstein R., Lode H.N. Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers (Basel). 2018;10(10):387. doi: 10.3390/cancers10100387.Siebert N., Troschke-Meurer S., Marx M., Zumpe M., Ehlert K., Gray J., Garaventa A., Manzitti C., Ash S., Klingebiel T., Beck J., Castel V., Valteau-Couanet D., Loibner H., Ladenstein R., Lode H.N. Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers (Basel). 2018;10(10):387. doi: 10.3390/cancers10100387.Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: 27 November 2017. U.S. Department of Health and Human Services, National Institutes of Health National Cancer Institute. [Electronic resource]: URL: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: 27 November 2017. U.S. Department of Health and Human Services, National Institutes of Health National Cancer Institute. [Electronic resource]: URL: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.Amoroso L., Fagioli F., Tondo A., Conte M., Badino C., Di Cataldo A., Viscardi E., De Leonardis F., De Ioris M.A., Luksch R. Strategies to manage the adverse eff ects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review. Support Care Cancer. 2025;33(3):153. doi: 10.1007/s00520-024-09135-5.Amoroso L., Fagioli F., Tondo A., Conte M., Badino C., Di Cataldo A., Viscardi E., De Leonardis F., De Ioris M.A., Luksch R. Strategies to manage the adverse eff ects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review. Support Care Cancer. 2025;33(3):153. doi: 10.1007/s00520-024-09135-5.Keyel M.E., Reynolds C.P. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics. 2018;13:1–12. doi: 10.2147/BTT.S114530.Keyel M.E., Reynolds C.P. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics. 2018;13:1–12. doi: 10.2147/BTT.S114530.Lammie G., Cheung N., Gerald W., Rosenblum M., Cordoncardo C. Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas – an immunohistochemical study. Int J Oncol. 1993;3(5):909–15. doi: 10.3892/ijo.3.5.909.Lammie G., Cheung N., Gerald W., Rosenblum M., Cordoncardo C. Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas – an immunohistochemical study. Int J Oncol. 1993;3(5):909–15. doi: 10.3892/ijo.3.5.909.Lode H.N., Valteau-Couanet D., Gray J., Luksch R., Wieczorek A., Castel V., Ash S., Laureys G., Papadakis V., Owens C., Garaventa A., Manzitti C., Siebert N., Troschke-Meurer S., Glogova E., Poetschger U., Ladenstein R.L. Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial. J Clin Oncol. 2019:15_suppl:10014. doi: 10.1200/JCO.2019.37.15_ suppl.1001.Lode H.N., Valteau-Couanet D., Gray J., Luksch R., Wieczorek A., Castel V., Ash S., Laureys G., Papadakis V., Owens C., Garaventa A., Manzitti C., Siebert N., Troschke-Meurer S., Glogova E., Poetschger U., Ladenstein R.L. Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial. J Clin Oncol. 2019:15_suppl:10014. doi: 10.1200/JCO.2019.37.15_ suppl.1001.Brennan F.R., Morton L.D., Spindeldreher S., Kiessling A., Allenspach R., Hey A., Muller P.Y., Frings W., Sims J. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs. 2010;2(3):233–55. doi: 10.4161/mabs.2.3.11782.Brennan F.R., Morton L.D., Spindeldreher S., Kiessling A., Allenspach R., Hey A., Muller P.Y., Frings W., Sims J. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs. 2010;2(3):233–55. doi: 10.4161/mabs.2.3.11782.Blom T., Lurvink R., Aleven L., Mensink M., Wolfs T., Dierselhuis M., van Eijkelenburg N., Kraal K., van Noesel M., van Grotel M., Tytgat G. Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients. Front Oncol. 2021;10:601076. doi: 10.3389/fonc.2020.601076.Blom T., Lurvink R., Aleven L., Mensink M., Wolfs T., Dierselhuis M., van Eijkelenburg N., Kraal K., van Noesel M., van Grotel M., Tytgat G. Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients. Front Oncol. 2021;10:601076. doi: 10.3389/fonc.2020.601076.Андреева Н.А., Бездольнова Е.О., Качанов Д.Ю., Смирнова А.Б., Телешова М.В., Уталиева Д.Т., Хамин И.Г., Шаманская Т.В. Офтальмологическая токсичность анти-GD2-иммунотерапии (динутуксимаб бета) у пациента с нейробластомой группы высокого риска: описание клинического наблюдения и обзор литературы. Педиатрия. Журнал им. Г.Н. Сперанского. 2021;100(3):248–57. doi: 10.24110/0031-403X-2021-100-3-248-257.Andreeva N.A., Bezdolnova E.O., Kachanov D.Yu., Smirnova A.B., Teleshova M.V., Utalieva D.T., Khamin I.G., Shamanskaya T.V. Ophthalmic toxicity of anti-GD2 immunotherapy (dinutuximab beta) in a patient with highrisk neuroblastoma: a case report and literature review. Pediatriya. Zhurnal im. G.N. Speranskogo = Pediatrics. Journal named after G.N. Speransky. 2021;100(3):248–57. (In Russ.)].Papadakis V., Kelaidi C., Zisaki K., Antoniadi K., Pitsoulakis G., Polychronopoulou S. Dinutuximab beta-related severe neurotoxicity: Resolution with the use of plasmapheresis. Pediatr Blood Cancer. 2022;69(4):e29465. doi: 10.1002/pbc.29465.Papadakis V., Kelaidi C., Zisaki K., Antoniadi K., Pitsoulakis G., Polychronopoulou S. Dinutuximab beta-related severe neurotoxicity: Resolution with the use of plasmapheresis. Pediatr Blood Cancer. 2022;69(4):e29465. doi: 10.1002/pbc.29465.Xu J., Xie L., Sun X., Guo W. Irinotecan-Induced Diarrhea during a Protracted Administration Schedule for Pediatric Sarcomas – Mechanisms and Clinical Applications. Clin Oncol. 2022;7:1953. ISSN: 2474-1663.Xu J., Xie L., Sun X., Guo W. Irinotecan-Induced Diarrhea during a Protracted Administration Schedule for Pediatric Sarcomas – Mechanisms and Clinical Applications. Clin Oncol. 2022;7:1953. ISSN: 2474-1663.33 Stein A., Voigt W., Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51–63. doi: 10.1177/1758834009355164.33 Stein A., Voigt W., Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51–63. doi: 10.1177/1758834009355164.Pappo A.S., Lyden E., Breitfeld P., Donaldson S.S., Wiener E., Parham D., Crews K.R., Houghton P., Meyer W.H.; Childrenʼs Oncology Group. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Childrenʼs Oncology Group. J Clin Oncol. 2007;25(4):362–9. doi: 10.1200/JCO.2006.07.1720.Pappo A.S., Lyden E., Breitfeld P., Donaldson S.S., Wiener E., Parham D., Crews K.R., Houghton P., Meyer W.H.; Childrenʼs Oncology Group. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Childrenʼs Oncology Group. J Clin Oncol. 2007;25(4):362–9. doi: 10.1200/JCO.2006.07.1720.Wagner L.M., McAllister N., Goldsby R.E., Rausen A.R., McNallKnapp R.Y., McCarville M.B., Albritton K. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007;48(2):132–9. doi: 10.1002/pbc.20697.Wagner L.M., McAllister N., Goldsby R.E., Rausen A.R., McNallKnapp R.Y., McCarville M.B., Albritton K. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007;48(2):132–9. doi: 10.1002/pbc.20697.European Medicines Agency (EMA). European Public Assessment Report (EPAR) for dinutuximab beta (Apeiron): EMA/263814/2017, fi rst published 15 May 2017.European Medicines Agency (EMA). European Public Assessment Report (EPAR) for dinutuximab beta (Apeiron): EMA/263814/2017, fi rst published 15 May 2017.

The authors declare that there are no conflicts of interest present.